From: Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America
No experience at all
35 (39%)
Etanercept
5 (5%)
Abatacept
0 (0.0%)
Adalimumab
Infliximab
4 (4%)
Anakinra
1 (1%)
Tocilizumab
Rituximab
29 (32%)
Canakinumab
0 (0%)
Multiple
16 (18%)
Other